Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial. (2021)
Attributed to:
Evaluating new healthcare technologies in cancer
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.eururo.2021.06.023
PubMed Identifier: 34274134
Publication URI: http://europepmc.org/abstract/MED/34274134
Type: Journal Article/Review
Volume: 80
Parent Publication: European urology
Issue: 4
ISSN: 0302-2838